Novel On-Target Restoration of a Split T Cell-Engaging Antibody for Precision Immunotherapy of Multiple Myeloma

T cell-engaging immunotherapies are changing the therapeutic landscape of cancer. However, suitable target antigens are scarce, restricting these strategies to very few tumor types. To overcome this limitation, we developed a T cell-engaging antibody derivative, which comes in two complementary halves and addresses antigen combinations instead of single molecules. Each half, originally coined hemibody, contains an antigen specific single-chain variable fragment fused to either the variable light (VL) or variable heavy (VH) chain domain of an anti-CD3 antibody.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research